And so another day has begun. We hope yours is getting off to a good start. For us, it is a bright beginning - the dog has pooped, the heirs are off to school and the hot coffee is beckoning…

Roche has promoted Juergen Schwiezer to head its diagnostics division, replacing Severin Schwan, who becomes ceo on March 4. Schwiezer, 62, who leads the unit in Europe and Latin America, starts on Jan. 1. Franz Humer, the currrent ceo, will remain chairman and Schwan, 40, who joined Roche as finance officer in 1993, will become the youngest ceo to ever run Roche.

Glaxo will charge $490 for a full course of Cervarix, its new HPV vaccine, in the UK and Germany, which matches the price set by Merck for Gardasil. The Glaxo vaccine goes on sale in the two countries today, although the European Union cleared the product for sale in 27 countries last month.

The patent on Lilly’s Zyprexa will remain intact until 2011 now that the US Supreme Court has declined to hear a challenge from Dr. Reddy’s, Teva and a Novartis unit. The move, or lack thereof, reaffirms a 2005 court ruling.

Want to know what biotech execs and investment managers think of the biotech sector in the US and Europe? Global Life Sciences Ventures conducted a survey and found that 68 percent see the future of the European biotech sector as fairly or highly positive, down from 75 percent. You can read the rest here.

And finally, Mark McDade will go kayaking sooner than he expected. The ceo of PDL BioPharma, which has been under pressure to revamp amid charges of wasteful spending by its biggest shareholder, is leaving immediately. PDL chairman Patrick Gage will be the interim CEO. Karen Dawes was elected chairwoman to replace Gage. And PDL is actively seeking a buyer, too.